Business Wire

ABP-PUBLISHING

29.6.2022 11:02:08 CEST | Business Wire | Press release

Share
ABP Publishing Continued Growing in 2022 According to the Report for the 1st Quarter

ABP Publishing almost doubled its sales in the German market in Q1 2022 compared to the same period of 2021. Other target markets showed raise according to the evolved plan. Thus, the company continues the growing trend line.

For 2022 the company management set the aim of 30% growth in general. According to the reports for Q1, it seems to be an achievable goal. For instance, the income from the German titles rose 70% compared to Q1 2021 and 20% - to Q4 2021.

“We have built an effective planning system and watch rights acquisition, production, and marketing develop according to that long-term plan, - says Andrey Mishenev, CEO. – Such a unitary approach to the management lets us not only produce a big number of new titles but also achieve the target sales rate."

The growing trend is noticed in Italian and Turkish markets. There the company chose a different way of selecting titles and produces mostly the bestselling books by the key authors. As a result, the beginning of the year showed a raise in consumption on streaming platforms in Turkey. The users are interested in economics and business and highly estimate books by Robert Kiyosaki.

As for the stable markets such as France, ABP Publishing reports slower, but steady growth. The company counts on a diverse catalogue with a balance of international bestsellers and novelties by local authors.

“We are proud to have worked with the autobiography by Will Smith in French. The copyright holder has firm requirements for a voice-over and the quality of performance and sound, but we managed to meet all the demands, - says Viktoria Salnikova, Chief Editor. – Among others, I would mention the books Amazon Unbound by Brad Stone in German, The Path by Tony Robbins in Italian, and an anniversary edition of The 7 Habits by Highly Effective People by Stephen Covey in Turkish. I believe these books will inspire our listeners as they have done us, at ABP Publishing.”

About ABP Publishing

ABP Publishing is a publisher of non-fiction digital-only audiobooks in different languages. The company comprises five divisions: ABP Verlag in Germany, ABP Editions in France, ABP Editore in Italy, ABP Yayinevi in Turkey, and ABP Publishing in other markets. The total publishing portfolio includes more than 700 titles.

Link:

ClickThru

Social Media:

https://www.facebook.com/abpverlag/

https://www.facebook.com/abpeditions

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release

Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla

RQM+ Launches SMART Solutions Life Cycle Partnership Model12.3.2026 14:30:00 CET | Press release

Helps MedTech Companies Navigate MDR, IVDR, and AI-Enabled Device Development RQM+, a leading MedTech CRO offering regulatory consulting, clinical trial, laboratory, and reimbursement services, today announced the launch of SMART Solutions, a life cycle partnership model designed to help medical device and diagnostics companies manage growing regulatory and development complexity. SMART Solutions introduces a strategy-led operating framework that unifies regulatory, quality, clinical, reimbursement, and laboratory expertise to support MedTech companies across the entire product life cycle to help reduce risk from early development through post-market. “MedTech companies are navigating unprecedented complexity as regulatory expectations evolve, product innovation accelerates, and post-market expectations are expanding,” said John Potthoff, Ph.D., chief executive officer of RQM+. “SMART Solutions moves beyond traditional consulting by providing an integrated life cycle partnership that h

Cryptio Raises $45m Series B as Digital Assets Move Into Regulated Financial Markets12.3.2026 14:06:00 CET | Press release

The system of record for tokenized finance – ERP infrastructure for institutions operating in digital assets Cryptio, a leader in financial data transformation and enterprise resource planning (ERP) applications for regulated digital assets, announced today a $45 million Series B funding round co-led by BlackFin Capital Partners and Sentinel Global, with participation from 1kx, Alven, BlueYard Capital and Ledger Cathay Capital. Banks, exchanges, asset managers, including Société Générale’s SG Forge, Circle, Gemini, and Securitize rely on Cryptio to ensure financial integrity across their digital assets businesses. Existing ERP systems fall short for digital assets Traditional ERP and accounting systems were not designed for blockchain-native assets, real-time reporting, or modern custody frameworks. As regulated financial institutions expand into stablecoins, tokenized securities and other on-chain instruments, these limitations create material operational and reporting challenges. Cry

HyperLight Introduces 145 GHz Reference Modulators to Enable 448Gbps per Lane Datacom and 260GBaud Telecom Development12.3.2026 14:03:00 CET | Press release

HyperLight Corporation, creator of the TFLN Chiplet™ platform, today announced the release of its 145 GHz Packaged Intensity Modulator (IM), expanding the company‘s high-speed modulator portfolio. The new device is designed for ultra-wide modulation bandwidth, high signal fidelity, and stable operation control, enabling 448 Gbps per lane intensity-modulated-direct-detection (IMDD), 260 GBaud coherent links, and broadband RF photonics systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312319685/en/ Fig. 1: HyperLight’s 145 GHz intensity modulator for 448Gbps per lane IMDD and 260GBaud coherent applications, with operational electro-optical bandwidth >145GHz, stable bias control, 0.8 mm-connector; available in O-, C-, and L-bands. As symbol rates and analog bandwidth requirements continue to rise across data center interconnects, AI-driven photonics infrastructure, and laboratory test environments, system architects in

Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences12.3.2026 14:00:00 CET | Press release

Transaction deepens insights into Sec61 selectivity for targeted protein degradation, supporting accelerated development of Enodia’s novel small-molecule inhibitors Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, and Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Enodia has acquired Kezar’s assets from its Sec61-based discovery and development program. The acquisition enables Enodia to advance its understanding of Sec61 selectivity mechanisms, expanding biological and translational insights for faster progression toward key clinical milestones. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312627573/en/ Under the terms of the purchase agreement between Enodia and Kezar, Kezar w

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye